EBV: A phase 2 trial of tabelecleucel in people with Epstein-Barr virus associated diseases

This trial is testing a type of CAR-T cell therapy in people with Epstein-Barr virus associated diseases.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT04554914

Trial aim and background

The aim of this study is to assess the efficacy and safety of tabelecleucel in people with Epstein-Barr virus (EBV) associated diseases that is newly diagnosed or has not responded to previous treatment(refractory) or has come back after treatment (relapsed). 

Tabelecleucel is a new allogeneic (donor) CAR-T cell therapy. Current CAR-T cell therapies use T cells from the person who is going to have the therapy. These cells are collected, processed, genetically modified in a lab to recognise lymphoma cells, grown, and then given back to the person having treatment. This process can take a few weeks. The new therapy will use CAR-T cells made from donor T cells. This is called ‘allogeneic’ CAR-T cell therapy. Because the process uses donor cells, they can be collected and processed in advance, reducing the manufacturing time involved in CAR-T cell therapy. It might also be possible to use them in people who do not have enough of their own healthy T cells to be collected.

EBV is a very common virus that also causes glandular fever. The vast majority of people with EBV do not go on to develop lymphoma but some types of lymphoma have been linked to EBV.

Who can enter

Anyone with an EBV positive disorder may be eligible for this trial.

Locations

Recruitment for adults is taking place at the University Hospital Birmingham NHS Foundation Trust

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/record/NCT04554914 

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.